Assessing Ba Be Studies Methods

By Author: Ravinder Singh
Total Articles: 3
Comment this article

BA BE studies are required to ensure therapeutic equivalence between a pharmaceutically equivalent test drug and a generic drug or reference drug. BA/BE studies are finished Early and late clinical trial definitions, Formulations utilized as a part of clinical trial and steadiness studies. Submission of application for new drugs under schedule Y should be required to furnish the bioavailability and bioequivalence data, that is, mainly focus on the drug release from the pharmaceutical dosage form and subsequent absorption into the systemic circulation.

Bioavailability (BA) is defined as the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

• Methods for assessing the bioavailability
• Pharmacokinetics methods
• This method reflects the therapeutic effectiveness ...
... of a drug. Thus these are indirect methods. Plasma-level time studies Urinary excretion studies
• Pharmacodynamics methods
• This method involves direct measurement of drug effect on a physiologic process as a function of time. Acute pharmacologic response therapeutic response

Biologics and Biosimilars team includes Clinical Research professional, Physicians, Medical Writers, Safety Experts, Bio analytics with extensive experience in supporting development of Biosimilars for Indian and Global Registration. The team works with a focus of developing Veeda CR as a leading service provider in the field of Biologics - both novel and Biosimilars. We understand that, this class of drug provides exceptional challenges and requires in-depth knowledge and 'out of the box' thinking, which our group is capable of.

We aim to provide services at three levels. Firstly, as a CRO we will undertake to develop your Biological drug in the clinical environment which is mandated for its acceptance in the major markets of the world. At a higher level, we would aim to advise your in-house project team on the most strategic ways forward with the molecule which you have developed. This means an intense focus on the ultimate markets for which you are aiming and the customizing of the clinical trials program to meet those markets. In a perfect world, it would be possible to have one series of trials for all markets but regulatory differences between countries mean, for instance, that the reference drugs may be different.
Bioequivalence is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.

There are four types of equivalences:
1. Chemical equivalence
2. Pharmaceutics equivalence
3. Therapeutic equivalence
4. Bioequivalence

Veeda CR is one of the leading Independent clinical research companies in India with an In-depth Clinical research knowledge in CRO clinical trials, CRO pharma, BA BE studies etc.